Novogen to stick with anticancers in rough climate
This article was originally published in Scrip
Executive Summary
The Australian biotech firm Novogen is to put its cardiovascular and anti-inflammatory research programmes on hold and focus its cash reserves on its anticancer compounds as a result of the tougher economic climate.